Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Des Devel Ther. 2013 Nov 22;7:1399-408. doi: 10.2147/DDDT.S48937. eCollection 2013.

Canagliflozin: a novel treatment option for type 2 diabetes.

Author information

1
University of Florida College of Medicine, Department of Community Health and Family Medicine, Gainesville, FL, USA.

Abstract

Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk-benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, thereby increasing urinary glucose excretion. It reduces hemoglobin A1c by approximately 0.37%-1.16%; it also reduces the patient's weight and systolic blood pressure and has a low risk for hypoglycemia. Adverse effects include an increased risk of urinary tract infections and genital mycotic infections. In this manuscript we review canagliflozin and its potential role in management of type 2 diabetes mellitus.

KEYWORDS:

SGLT2 inhibitor; canagliflozin; oral hypoglycemic; type 2 diabetes

PMID:
24285921
PMCID:
PMC3840773
DOI:
10.2147/DDDT.S48937
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center